Please login to the form below

Not currently logged in


This page shows the latest Remestemcel-L news and features for those working in and with pharma, biotech and healthcare.

Novartis pulls out of Mesoblast deal

Novartis pulls out of Mesoblast deal

Shares in Mesoblast dropped sharply after Novartis pulled out of a deal announced earlier this year to collaborate on COVID-19 medicine remestemcel-L, citing poor trial data. ... When it announced a deal with Australian inflammatory disease specialist

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...